Kornimate/medical-research-clean huggingface dataset:
influence of platelet concentrates on wound healing

Conditions: Platelet-Rich Plasma; Wound Healing Delayed

Summary: chronic soft tissues defects can extend into the fat layer or even deeper and can cause functional disadvantages. split-thickness skin grafts (stsgs) used to cover these wounds have varying success rates. to improve wound healing in chronic wounds the authors have studied the application of autologous platelet concentrates in a human keratinocyte culture model in vitro and in a combination with surgical procedures in vivo as second line therapy in patients with initially failed wound closure.

for in vitro testing on keratinocytes a platelet-mediator concentrate (pmc) was processed with a commercially available bed-side system (atr®, curasan, germany). in a clinical study soft tissue defects (n=5) were treated using a combination of surgical debridement and autologous platelet rich plasma (prp). time of healing as determined by epithelization as well as laser doppler imaging to visualize blood flow were analyzed. additionally, changes in "ease of surgical wound closure" were determined. finally, the quality of life of patients was assessed using a validated questionnaire.

Eligibility criteria:
inclusion criteria: * exposed tendons, ligaments or bone for \>3 weeks * no healing tendency exclusion criteria: * sepsis * intensive care treatment * continuous smoking * pregnancy or breast feeding women * participants of other studies.

Keywords: platelet-rich plasma laser doppler imaging growth factors wound healing chronic wound healing disorder wound quality of life
the use of brace to retrain hemiparetic gait

Conditions: Stroke Nos Without Residual Deficits

Summary: the purpose of this study is to verify if the incorporation of a new brace, which assists in gait rehabilitation, can contribute to the rehabilitation process for stroke patients.

objective to compare the behavior of plantar pressure peak distribution, before and after training using a brace for gait rehabilitation. method the brace was developed with the aim of promoting better biomechanical alignment, as well as providing proprioceptive information in order to stimulate action in the knee's flexor muscle groups, thus facilitating the activation pattern contrary to what occurs during genu recurvatum. we conducted a quasi-experimental "before and after" study with twelve hemiparetic adult patients who had genu recurvatum in the gait. the plantar pressure peaks were compared at the various moments of the study.

Eligibility criteria:
inclusion criteria: * the presence of hemiparesis after the stroke, with an evolution time of between 6 and 24 months, the ability to walk without using assistive aids, and the presence of genu recurvatum during the mid-stance in the gait. exclusion criteria: * conditions that would preclude evaluation and training with the brace; for example, the presence of contractures or fixed deformities in the lower limbs, and moderate to severe impairments related to cognition, perception, attention, or language

Keywords: stroke, rehabilitation, hemiparesis, gait training
pharmacokinetics of micafungin during continuous venovenous hemofiltration

Conditions: Candida Sepsis

Summary: micafungin is a cyclic lipopeptide antifungal agent of the echinocandin class. members of this class of antifungal agents are known to inhibit the synthesis of glucan polymers in fungal cell walls. the spectrum of activity of micafungin includes candida (all species, including strains resistant to fluconazole), aspergillus, and pneumocystis. in intensive care patients continuous venovenous haemodiafiltration (cvvhdf) is a well-established extracorporal renal replacement therapy with a high clearance rate. pharmacokinetic studies of antifungal agents in critically ill patients treated with cvvhdf are rare. elimination of any given drug by renal replacement therapy is determined by several major factors which are membrane specific, due to physico-chemical properties of the drug and characteristics of the renal replacement technique used. ten intensive-care patients with acute renal failure and suspected or proven candida infection are included into the study. 100 mg micafungin will be infused over a period of sixty minutes via a central venous catheter, different from the venous catheter used for cvvhdf. blood samples will be drawn on days 1 and 2 from the arterial and venous line of the extracorporeal circuit at 0, 2, 4, 6, 8 and 24h after starting the infusion. plasma and ultrafiltration samples, collected from the outlet of the ultrafiltrate compartment of the hemofilter, will be taken at corresponding times. the following pharmacokinetic parameters will be determined: area under the curve (auc), half-live (t1/2), maximum plasma concentration (cmax) and elimination fraction.


Eligibility criteria:
inclusion criteria: * age 19 to 70 years * suspected or proven candida infection requiring parenteral antifungal therapy. * continuous venovenous hemo(dia)filtration or cica hd because of an acute renal failure. exclusion criteria: * known history of hypersensitivity to echinocandins. * an expected survival of less than three days. * known alcohol dependency * known epilepsy * known pregnancy * known liver failure * soor oesophagitis
montelukast in seasonal allergic rhinitis - spring 2001 study (0476-235)

Conditions: Seasonal Allergic Rhinitis

Summary: this study will assess the treatment effect of montelukast versus placebo over a 2 week period in patients with seasonal allergic rhinitis. loratadine is included in the study as an active comparator.


Eligibility criteria:
inclusion criteria: * patient has a documented history of season allergic rhinitis symptoms that flare up during the study season * patient is a nonsmoker * patient is in good general health exclusion criteria: * patient is hospitalized * patient is a woman who is \<8 weeks postpartum or is breast-feeding * patient has had major surgery in the past 4 weeks * patient intends to move or vacation away during the study * patient is a current or past abuser of alcohol or illicit drugs
cognitive impairment in older emergency department users and associated adverse outcomes

Conditions: Cognitive Frailty; Physical Frailty; Older Emergency Department Users

Summary: this study examines the prevalence and incidence of older er users with cognitive impairment (i.e., dementia and/or delirium) using the er2 item temporal disorientation in older ed users who are participants of the er2 cohort study database.

the emergency departments (eds) in north america are under duress because of overcrowding, delays and diversions, which increase to epidemic proportions. the aging of canadian's population amplifies the magnitude of this situation because older ed users are the fastest increasing group of ed users and they have complex and specific needs. there are simple interventions with which providers must proceed in order to cure or prevent short-term ed adverse events. delirium, motor deconditioning, polypharmacy-related adverse drug reactions, and inappropriate home support are the main conditions to target when taking care of older ed users. we previously demonstrated that acting on these conditions may significantly accelerate the discharge and significantly reduce the length of ed and hospital stay. evidence-based medicine showed that simple and early interventions may prevent delirium (e.g., through hydration, avoiding restraint, mobilizing and satisfying basic needs, time and place reorientation) and motor deconditioning (e.g., through encouraging mobility, up to chair at mealtime during daytime hours, providing appropriate walking aid) in older patients. medication reconciliation is also an efficient intervention to prevent adverse drug reactions. furthermore, an early assessment of home support is a crucial step in adjusting services for an early and smooth discharge back home. based on this evidence, we have modified the 6-item emergency room evaluation and recommendations (er2) by adding an interventional component to the assessment portion of the tool. the interventional part depends on the assessment's results and is based on recommendations designed to encourage easy and basic interventions that prevent delirium, motor deconditioning, adverse drug interactions and inappropriate home support. these recommendations are based on answers to the er2 items

Eligibility criteria:
inclusion criteria: - an unplanned ed visit and to be on a stretcher exclusion criteria: -
cardiac resynchronization therapy (crt)-narrow-dp/dt-study

Conditions: Heart Failure

Summary: goal is to examine the efficy of cardiac resynchronization therapy in heart failure patients with narrow qrs complex and optimized medical treatment but echocardiographic desynchronization detection as well as the positve increase of the intraoperative pressureincreasespeed in reverse remodelling and a secondary improvement of functional parameters


Eligibility criteria:
inclusion criteria: * ef \< 35% * chd or dilate cardiomyopathy * sinus rhythm * nyha iii (or iv but stable recompenstated) * qrs \< 120 ms 2-3 of the following: * lv-fillingtime \< 40% of the cyclelength * tdi septal-lateral (lv basal) \> 60ms * 2d-strain-score \> 9 points exclusion criteria: * tricuspid or artificial valve * av block ii or iii or pq time \> 250ms * revasculisation or condition after cardiac surgery \< 3 months * myocardial infarction or bypass op \< 3 months * hytertrphic obstructive cardiomyopathy, constrictive pericarditis * intravenous catecholamines because of hf * manifeste hyperthyreoses * kidney failure (creatine \>2,5 mg/dl) * no written informed consent * no compliance * participation in another study * life expectancy \< 1 year * patients \< 18 years * pragnancy or no safe contraception

Keywords: narrow qrs crt
radiopaque matrix mk-8591 implant in participants at low-risk for human immunodeficiency virus type 1 (hiv-1) infection (mk-8591-043)

Conditions: Human Immunodeficiency Virus; HIV

Summary: the purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (pk) of an islatravir (isl)-eluting implant. participants will receive an implant placed in the upper arm for approximately 52 weeks with 8 weeks of follow-up in the base study. a subset of participants will also receive a second implant for an additional 12 weeks before 8 weeks of follow-up in the substudy.


Eligibility criteria:
inclusion criteria: * is in good health * is confirmed human immunodeficiency virus (hiv)-uninfected * is at low risk of hiv infection * for males, uses contraception in accordance with local regulations regarding contraception use for those participating in clinical trials * for females, is not pregnant or breastfeeding and one of the following applies: * is not a participant of childbearing potential (pocbp) * is a pocbp and uses an acceptable contraception method or is abstinent exclusion criteria: * has an active diagnosis of hepatitis (b or c) due to any cause * has a history of malignancy ≤5 years before signing informed consent * has a history or current evidence of any condition that might confound study results or interfere with study participation * has a history of keloid in upper arm or presence of tattoo, scar, or other physical finding that could interfere with implant placement (the contralateral arm may be used if the findings are limited to 1 arm) * is taking or is expected to take immunosuppressants during the study
predicting burnout in nurses

Conditions: Burnout, Healthcare Workers

Summary: the purpose of this study is to develop a technology to predict burnout in rns by measuring workplace, psychological, and physiological factors experienced by nurses.


Eligibility criteria:
inclusion criteria: * employed as a registered nurse at mayo clinic rochester or mayo clinic florida. * primary work assignment is one of the following: medical-surgical units, operating and recovery rooms, emergency room, intensive/cardiac care units, or other special care units (including neonatal intensive care units and newborn nurseries). * proficient in written and spoken english. * able to provide written informed consent. exclusion criteria: - any exception to above criteria.

Keywords: registered nurses artificial intelligence wearable
evaluation of postoperative acute kidney injury (aki) incidence and risk factors in patients underwent pneumonectomy

Conditions: Acute Kidney Injury; Pneumonectomy; Status; Complication,Postoperative

Summary: acute kidney injury (aki) is a critical complication associated with a high incidence of morbidity and mortality that can occur in critically ill patients and after major surgical procedures. the aim of this study is to identify the incidance and outcomes of patients underwent pneumonectomy, defined by kidney disease improving global outcomes (kdigo) criteria.

acute kidney injury (aki) is a critical complication associated with a high incidence of morbidity and mortality that can occur in critically ill patients and after major surgical procedures. although there is a decrease in pulmonary damage with restrictive fluid management and protective ventilatory strategies in patients who underwent wide lung resection to prevent pulmonary edema development after resection, the relative hypovolemia and hypoperfusion developed in patients may lead to renal dysfunction. the incidence of aki after thoracic surgery can be up to 15% and is associated with prolonged length of stay (los) in hospital. the incidence of aki is higher in patients with extensive resection such as pneumonectomy compared with lobectomy and wedge resection. since aki is not only a rare complication but also a risk factor for mortality, it is important to identify the incidence and risk factors of aki, to prevent aki and related complications and to improve patients outcomes. in this study incidence of aki was defined using the kdigo criteria according to the change of serum creatine levels. 166 patients who underwent pneumonectomy from january 2008 to december 2018 included the retrospective observational study. demographic data, intraoperative data, rates of complications, risk factors for aki, mortality, lenght of stay in intensive care unit (i̇cu) and hospital were evaluated. aki was defined using the kdigo criteria according to the serum creatinine levels. the spss 11.5 program was used for statistical analysis.

Eligibility criteria:
inclusion criteria: * patients underwent pneumonectomy, from january 2008 to december 2018 exclusion criteria: * chronic kidney disease

Keywords: acute kidney injury pneumonectomy
study of recombinant factor viia fusion protein (rviia-fp, csl689) for on-demand treatment of bleeding episodes in patients with hemophilia a or b with inhibitors

Conditions: Hemophilia A With Inhibitors; Hemophilia B With Inhibitors

Summary: the purpose of this study is to investigate the pharmacokinetics (pk), efficacy, and safety of rviia-fp (csl689). the study will enroll approximately 54 male subjects, 12 to 65 years of age, with hemophilia types a or b who have developed inhibitors to fviii or fix. the study consists of 3 sequential parts (parts 1, 2, 3): the purpose of part 1 (pk part) is to evaluate the pk of a single treatment of csl689 (low dose or high dose) and compare with the pk of a single treatment of eptacog alfa (low dose or high dose). in part 1, csl689 and eptacog alfa will be given by the doctor at the study center. the purpose of part 2 (dose-evaluation part) is to identify which of the 2 tested dose levels of csl689 shows the best efficacy and safety in stopping acute bleeding events (this dose will be called the "population best dose"). the purpose of the final part 3 (repeated-dose part) is to confirm the efficacy and safety of the "population best dose" identified in part 2. in parts 2 and 3, subjects will self-administer a specified number of csl689 infusions at home on-demand (ie, when a bleeding event occurs), will keep an electronic diary, and will visit the center at monthly intervals. this study is expected to last for up to 16 months for the subjects participating in all 3 parts, and up to 9 months for the subjects participating in part 3 only.


Eligibility criteria:
inclusion criteria: * male subjects with hemophilia a or b and inhibitors. * age ≥ 12 and ≤ 65 years. * high responding inhibitor with documented historical inhibitor titer \> 5 bethesda units/ml. exclusion criteria: * congenital or acquired coagulation disorders other than hemophilia a or b. * ongoing immune tolerance induction therapy or planned during study. * known or suspected hypersensitivity to activated recombinant human fvii or to any excipient of csl689. * body mass index \> 30 kg/m². * major surgery within 28 days before screening or scheduled major and / or orthopedic surgery during the study. * advanced atherosclerotic disease (ie, known history of ischemic heart disease, or ischemic stroke). * any clinical signs or known history of thromboembolic events, including known deep vein thrombosis. * human immunodeficiency virus (hiv)-positive subjects who have low cluster of differentiation 4 (cd4)+ lymphocyte count (200/μl or less) at screening. * use of the following within the screening period or planned during study: a) plasma or coagulation factor concentrates other than rescue therapy or therapy during part 1, b) other platelet inhibitors, c) desmopressin, and d) fibrinolysis inhibitors, except if used as local treatment (eg, for oral bleeds).
in-office study of the hummingbird® in children 6 months-21 years old

Conditions: Ear Infection; Otitis Media

Summary: the objective of this study is to evaluate the safety and performance of the hummingbird® for the placement of ear tubes in children undergoing tympanostomy tube placement in an otolaryngology clinic using local anesthetic.

the hummingbird tympanostomy tube system (h-tts) is intended to deliver a tympanostomy tube (also referred to as a ventilation tube) through the tympanic membrane of the patient and is indicated to be used in office settings for children. the h-tts is intended to deliver a tympanostomy tube through the tympanic membrane (tm) of the patient. it combines the separate functions of creating a myringotomy, and positioning and placing a ventilation tube across the tm. the hummingbird tympanostomy tube system (h-tts) is a disposable surgical tool designed to deliver a tympanostomy tube ("ear tube") into the tympanic membrane of patients during a tympanostomy tube placement procedure. more than 1,000,000 ear tubes are inserted annually in the us, making it one of the most common surgical procedures performed in children. preceptis medical, inc. has developed the h-tts to reduce trauma, pain, and risk to the patient while reducing the overall surgical procedure time. the h-tts integrates the multiple surgical instruments necessary for current surgical procedure into a single, one-pass device. the h-tts creates an incision in the tympanic membrane ("ear drum") and inserts a tympanostomy tube with the push of a lever. thus, the h-tts allows placement of a tympanostomy tube with a single pass down the ear canal. the ear tube used with the h-tts is a standard, commercially available tympanostomy tube.

Eligibility criteria:
inclusion criteria: * scheduled to undergo tympanostomy tube insertion in the clinic. * children 6 months to 21 years old * signed parental consent, and child assent documents as applicable. * parent is fluent in english. exclusion criteria: * any condition that, in the opinion of the investigator, may place the subject at greater risk (e.g., child with developmental delay). * anatomy precludes sufficient visualization and access to the tympanic membrane.
a questionnaire survey study for exploring outcomes for patients with disc herniation

Conditions: Lumbar Disc Herniation

Summary: background: the selection of primary outcomes that reflect the real symptoms and conditions of patients is instrumental in clinical studies on the effectiveness of specific treatment modalities. this study aimed to explore the appropriate outcomes that reflect the real-world needs and concerns of patients with lumbar disc herniation (ldh) and provide a basis for designing related clinical trials. methods and findings: this cross-sectional nationwide web-based survey study was conducted in south korea in november 2022. patients who were diagnosed with ldh and had ldh-related radiating leg pain were enrolled. the questionnaire consisted of 5 parts: basic characteristics, disease onset, symptom and severity, priority symptoms for improvement, and important factors in treatment. overall, 500 patients (100 patients from the each age group) were enrolled.


Eligibility criteria:
inclusion criteria: * diagnosed of ldh * age 19-69 years * presence of ldh-related symptoms such as pain, numbness, weakness, or tingling in the legs * agree to informed consent form exclusion criteria: * severe mental illness and intellectual disabilities that prevented independence in answering the questionnaire
pupil dilation and analgesia nociception index

Conditions: Pain

Summary: pain assessment is crucial in clinical practice. currently, subjective self-report is considered the most appropriate method to evaluate pain. although several methods to assess pain objectively exist, the lack of a golden standard still remains. this pilot study assesses the changes in pupil dilation (pd) and the analgesia nociception index (ani) as a measure of pain in healthy, conscious, male volunteers in a highly standardized and individualized environment. nineteen subjects received three blocks of 4 individualized electrical stimulus intensities, ranging from no to severe pain. subjects reported their perceived severity of each individual stimulus, enabling the comparison of changes in pd and ani in relation to both administered stimulus intensities and perceived pain severities. pd and ani were measured before and after each administration of a stimulus.


Eligibility criteria:
inclusion criteria: * good health * no acute or chronic pain conditions * well rested exclusion criteria: * chronic treatment * bad health * daily use of analgetics or other medication * weekly tobacco use * weekly use of recreational drugs * more than 10 alcohol consumptions a week